Australia markets open in 7 hours 14 minutes

Idorsia Ltd (IDRSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
22.88-0.02 (-0.11%)
As of 10:07AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close22.90
Open22.88
Bid0.00 x 0
Ask0.00 x 0
Day's range22.88 - 22.88
52-week range16.85 - 31.19
Volume300
Avg. volume2,292
Market cap3.874B
Beta (5Y monthly)0.77
PE ratio (TTM)N/A
EPS (TTM)-3.42
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

    Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomniaCollaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022Idorsia L

  • GlobeNewswire

    Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

    Ad hoc announcement pursuant to Art. 53 LR Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg Allschwil, Switzerland – January 20, 2022Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals Japan today announce that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved PIVLAZ™ (clazosentan sodium) 150 mg, a selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral is

  • GlobeNewswire

    The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

    The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia As reported in the Lancet Neurology, daridorexant is the first insomnia medication to demonstrate an effect of a drug therapy to improve both nighttime symptoms and daytime functioning1Daridorexant 50 mg, showed significant improvement versus placebo on sleep onset, sleep maintenance, and total sleep timeDaridorexant 50 mg, which was evaluated in one of the two pivotal P